IP Library › Granted Patent US 11,413,263
Granted Patent B2
US 11,413,263 · App. 16/160,388 · Granted Aug 16, 2022

Reducing the risk of pathological effects of traumatic brain injury

Inventors: Kevin Hadley (Elkridge, MD); Terence Fealey (Marietta, GA); Julian E. Bailes (Morgantown, WV)
Assignee: DSM IP Assets, B.V.
A61K31/232A61K36/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,413,263
App. No.
16/160,388
Granted
Aug 16, 2022
Kind
B2
Abstract

The present disclosure provides methods and compositions for reducing the risk of pathological effects of traumatic brain injury.

Claims (19)

1. A method for reducing the risk of pathological effects of traumatic brain injury, comprising:

(a) administering to a subject who is at risk of traumatic brain injury a composition comprising 40-50 wt % docosahexaenoate (DHA) of the total fatty acid content, wherein the composition is administered prior to engagement in an activity associated with a risk of traumatic brain injury to reduce the risk of pathological effects of traumatic brain injury, wherein the composition has an eicosapentaenoate (EPA) content of less than 3 wt % of the total fatty acid content and a docosapentaenoic acid n-6 (DPA n-6) content of 12-18 wt % of the total fatty acid content, and wherein the subject at risk for traumatic brain injury is an athlete participating in a sport with occurrence of concussions.

2. A method for reducing the risk of pathological effects of traumatic brain injury, comprising:

(a) selecting a subject who is at risk of traumatic brain injury, wherein the subject at risk for traumatic brain injury is an athlete participating in a sport with occurrence of concussions; and

(b) administering to the subject a composition comprising 40-50 wt % docosahexaenoate (DHA) of the total fatty acid content, wherein the composition is administered in a prophylactically effective amount prior to engagement in an activity associated with a risk of traumatic brain injury to reduce the risk of pathological effects of traumatic brain injury, and wherein the composition has an eicosapentaenoate (EPA) content of about 3 wt % of the total fatty acid content and a docosapentaenoic acid n-6 (DPA n-6) content of 12-18 wt % of the total fatty acid content.

3. The method of claim 1 or 2 in which the DHA is in the form of an alkylester.

4. The method of claim 3 in which the DHA alkylester is a methyl, ethyl or propyl ester.

5. The method of claim 1 or 2 in which the DHA to EPA ratio is at least 10:1.

6. The method of claim 1 or 2 in which the DHA is obtained from a microbial oil.

7. The method of claim 6 in which the microbial oil is an algal oil.

8. The method of claim 6 in which the microbial oil is from Crypthecodinium cohnii.

9. The method of claim 6 in which the microbial oil is from Schizochytrium sp.

10. The method of claim 1 or 2 in which the traumatic brain injury is a closed head injury.

11. The method of claim 1 or 2 in which the composition is administered for at least 28 days prior to engaging in the activity associated with the risk of traumatic brain injury.

12. The method of claim 1 or 2 in which the composition is administered for at least 6 weeks prior to engaging in the activity associated with a risk of traumatic brain injury.

13. The method of claim 1 or 2 in which the effective amount is a dose of about 10 mg/kg body weight/day to about 40 mg/kg body weight/day of DHA.

14. The method of claim 1 or 2 in which the composition is an oral dosage form.

15. The method of claim 14 in which the oral dosage form is a gelatin capsule.

16. The method of claim 15 in which the gelatin capsule comprises from about 200 mg to about 1 g of DHA, and a pharmaceutically acceptable excipient.

Cited By (1)
US 12,262,720